MITO - Stealth BioTherapeutics Corp

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.7500
-0.2500 (-8.33%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.0000
Open3.0000
Bid2.7500 x 1100
Ask2.7600 x 1000
Day's Range2.6500 - 3.0100
52 Week Range2.6500 - 20.9900
Volume209,388
Avg. Volume160,822
Market Cap96.342M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.3140
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.38
  • Stealth BioTherapeutics Initiates First-in-Human Study of SBT-272
    PR Newswire

    Stealth BioTherapeutics Initiates First-in-Human Study of SBT-272

    Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the initiation of a first-in-human Phase 1 trial evaluating its second generation pipeline compound, SBT-272, in healthy subjects.

  • In wake of drug trial fail, Newton firm cuts most staff, top scientist quits
    American City Business Journals

    In wake of drug trial fail, Newton firm cuts most staff, top scientist quits

    A Newton biotech startup is making major changes after a late-stage drug trial failure, announcing this week that it has laid off 60% of its staff.

  • 4 Reasons Why Investors Should Buy Alexion (ALXN) in 2020
    Zacks

    4 Reasons Why Investors Should Buy Alexion (ALXN) in 2020

    Alexion's (ALXN) growth prospects look strong for 2020 as Soliris maintains momentum and Ultomiris gains further traction.

  • Benzinga

    The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied ...

  • MarketWatch

    Stealth BioTherapeutics' stock falls on trial failure

    Shares of Stealth BioTherapeutics tumbled 63% after it said a late-stage trial for its investigational treatment of primary mitochondrial myopathy, a muscular disease caused by genetic mutations, failed to meet the study's primary endpoint. Stealth said in a news release that it is reviewing its "operational resources" and plans to provide investors with additional guidance in January. Shares of the Newton, Mass.-based biotechnology company, which went public in February, are down 22% over the last three months. The SPDR S&P Biotech exchange-traded fund has gained 16% during the same three months.

  • Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 20, 2019: AAPL, BA, IAC, MITO, AKS

    Benzinga Pro's Stocks To Watch For Friday Apple (AAPL) - Shares were modestly higher Friday morning following several items: 1. Piper Jaffray analyst Mike Olson raised his price target on Apple from $290 ...

  • Stealth BioTherapeutics Provides Update on Phase 3 Trial of Elamipretide in Primary Mitochondrial Myopathy
    PR Newswire

    Stealth BioTherapeutics Provides Update on Phase 3 Trial of Elamipretide in Primary Mitochondrial Myopathy

    Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced top-line data from the Phase 3 MMPOWER-3 trial evaluating elamipretide for treatment of patients with primary mitochondrial myopathy (PMM). The study did not meet its primary endpoints assessing changes in the six-minute walk test and Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue Score. Safety results showed that treatment with elamipretide was well tolerated with most adverse events mild to moderate in severity.

  • Stealth Biotherapeutics to Present at Jefferies 2019 London Healthcare Conference
    PR Newswire

    Stealth Biotherapeutics to Present at Jefferies 2019 London Healthcare Conference

    BOSTON , Nov. 19, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...

  • Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength
    Zacks

    Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength

    Alexion's (ALXN) stock rises 10% in the year so far as Soliris maintains momentum and Ultomiris gains further traction.

  • Stealth BioTherapeutics Reports Third Quarter 2019 Financial Results And Recent Business Highlights
    PR Newswire

    Stealth BioTherapeutics Reports Third Quarter 2019 Financial Results And Recent Business Highlights

    BOSTON , Nov. 14, 2019 /PRNewswire/ --  Stealth BioTherapeutics  Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...

  • Stealth Biotherapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
    PR Newswire

    Stealth Biotherapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019

    BOSTON , Nov. 11, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...

  • Alexion (ALXN) Beats on Q3 Earnings, Lifts 2019 Guidance
    Zacks

    Alexion (ALXN) Beats on Q3 Earnings, Lifts 2019 Guidance

    Alexion (ALXN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.

  • Stealth BioTherapeutics Presents Data for Elamipretide on Cardiac Function in Barth Syndrome
    PR Newswire

    Stealth BioTherapeutics Presents Data for Elamipretide on Cardiac Function in Barth Syndrome

    BOSTON, Oct. 17, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the presentation of new data from the open-label extension portion of the Phase 2/3 TAZPOWER study evaluating elamipretide in patients with Barth syndrome. The findings, presented at the American Society of Human Genetics (ASHG) 2019 Annual Meeting in Houston, Texas, showed that treatment with elamipretide resulted in a 27% increase in average cardiac stroke volume, or the amount of blood pumped by the heart's left ventricle per contraction, from the trial baseline (40.8 mL) to week 36 (51.8 mL) of the open-label extension.

  • Company News For Oct 11, 2019
    Zacks

    Company News For Oct 11, 2019

    Companies in the news are: RARX, BBBY, PCG, MITO

  • Alexion (ALXN) Collaborates With Stealth BioTherapeutics
    Zacks

    Alexion (ALXN) Collaborates With Stealth BioTherapeutics

    Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.

  • Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases
    Business Wire

    Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases

    Alexion Pharmaceuticals, Inc. (ALXN) and Stealth BioTherapeutics Corp (MITO) today announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases. Currently being evaluated in a Phase 3 study in people with primary mitochondrial myopathy (PMM) - a genetic mitochondrial disease - elamipretide is a novel, potential first-in-class therapy that targets mitochondrial dysfunction.

  • Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration
    PR Newswire

    Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration

    BOSTON, Oct. 7, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced the presentation of pre-clinical data for its lead pipeline compound, SBT-272, at the 18th Annual Northeast Amyotrophic Lateral Sclerosis Consortium in Clearwater Beach, Fla. The data showed that treatment with SBT-272 was associated with a dose-dependent delay in the onset of neurological disease, a reduction in systemic markers of neurodegeneration and prolonged lifespan in a mouse model of amyotrophic lateral sclerosis (ALS). SBT-272, a mitochondrial targeting investigational molecule in pre-clinical development for the treatment of rare neurodegenerative diseases involving mitochondrial dysfunction, is expected to advance into Phase 1 first-in-man safety studies by year-end.

  • Stealth Biotherapeutics to Present at the 2019 Cantor Global Healthcare Conference
    PR Newswire

    Stealth Biotherapeutics to Present at the 2019 Cantor Global Healthcare Conference

    BOSTON , Oct. 1, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...

  • Stealth BioTherapeutics to Attend Upcoming Investor Conferences
    PR Newswire

    Stealth BioTherapeutics to Attend Upcoming Investor Conferences

    BOSTON , Sept. 20, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies ...

  • Stealth BioTherapeutics Enters Oversold Territory
    Zacks

    Stealth BioTherapeutics Enters Oversold Territory

    Stealth BioTherapeutics Corp (MITO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Stealth BioTherapeutics Sees Hammer Chart Pattern: Time to Buy?
    Zacks

    Stealth BioTherapeutics Sees Hammer Chart Pattern: Time to Buy?

    Stealth BioTherapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

  • Stealth BioTherapeutics Announces Appointment of Robert Weiskopf as Chief Financial Officer
    PR Newswire

    Stealth BioTherapeutics Announces Appointment of Robert Weiskopf as Chief Financial Officer

    BOSTON, Sept. 3, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the appointment of Robert Weiskopf as Chief Financial Officer (CFO). "We're delighted to welcome Rob to our team during this pivotal time in our growth trajectory," said Chief Executive Officer Reenie McCarthy.

  • PR Newswire

    Stealth BioTherapeutics Reports First Half 2019 Financial Results And Recent Business Highlights

    - Louis Lange M.D., Ph.D. joins Board BOSTON , Aug. 14, 2019 /PRNewswire/ --  Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and ...

  • Stealth BioTherapeutics to Host KOL Breakfast Symposium on the Potential of Elamipretide in Orphan Mitochondrial Disorders
    PR Newswire

    Stealth BioTherapeutics to Host KOL Breakfast Symposium on the Potential of Elamipretide in Orphan Mitochondrial Disorders

    BOSTON, July 2, 2019 /PRNewswire/ -- Stealth BioTherapeutics (MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the Company will host a key opinion leader (KOL) breakfast symposium on Thursday, July 11, 2019 at 8:00 a.m. ET in New York City. The event will focus on the potential of the Company's lead candidate, elamipretide, in Primary Mitochondrial Myopathy and Barth's Syndrome and showcase data from its ongoing clinical programs, including data which was recently presented at Mitochondrial Medicine Symposium 2019, posters from which are now available on the Company's website.

  • Celgene (CELG) Hits 52-Week High, Can the Run Continue?
    Zacks

    Celgene (CELG) Hits 52-Week High, Can the Run Continue?

    Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.